Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 108

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 108
---
,000 working capital loans. The
sponsor further agrees that such loans shall be converted into Private Placement Units, at the price of $10.00 per unit. To the extent
the amount of such loans is less than $1,100,000, the sponsor acknowledges and agrees that it (or, if applicable, it and any transferees
of Private Placement Units) shall surrender for cancellation any and all rights to up to an aggregate of 110,000 Private Placement Units
at $10.00 per unit. As of June 30, 2025, there was $695,825 outstanding and reported as share subscription receivable on the unaudited
balance sheet.

We incurred $8,898,201 of transaction costs, consisting
of $1,150,000 of cash underwriting fees, $6,900,000 of deferred underwriting fees, and $848,201 of other offering costs.

We intend to use substantially all of the funds
held in the trust account, including any amounts representing interest earned on the trust account, which interest shall be net of taxes
payable, if any, and excluding deferred underwriting commissions, to complete our initial business combination. We may withdraw interest
from the trust account to pay taxes, if any. To the extent that our share capital or debt is used, in whole or in part, as consideration
to complete an initial business combination, the remaining proceeds held in the trust account will be used as working capital to finance
the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

21

We intend to use the funds from the Subscription
Promissory Note primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses,
travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review
corporate documents and material agreements of prospective target businesses, structure, negotiate and complete an initial business combination.

In order to fund working capital deficiencies
or finance transaction costs in connection with an initial business combination, our sponsor or an affiliate of our sponsor or certain
of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete an initial business combination,
we may repay such loaned amounts out of the proceeds of the trust account released to us. In the event that a business combination does
not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts,